Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer
| العنوان: | Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer |
|---|---|
| المؤلفون: | Kyogo Itoh, Shigeki Shichijo, Nobutaka Iwakuma, Uhi Toh, Akira Yamada, Yoshito Akagi, Yuko Takao, Shuko Saku, Sayaka Sakurai, Mina Okabe |
| المصدر: | Cancer Science |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Adult, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Triple Negative Breast Neoplasms, Cancer Vaccines, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Basic and Clinical Immunology, Antigens, Neoplasm, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, advanced metastatic triple‐negative breast cancer, Adverse effect, Triple-negative breast cancer, Immunization Schedule, Aged, Aged, 80 and over, business.industry, General Medicine, Immunotherapy, Original Articles, mixed‐peptide vaccine, Middle Aged, early phase II trial, medicine.disease, Clinical trial, Vaccination, 030104 developmental biology, Treatment Outcome, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Vaccines, Subunit, Peptide vaccine, Female, Original Article, Cancer vaccine, immunotherapy, business, Peptides |
| الوصف: | We undertook an early phase II study of mixed 19‐peptide cancer vaccine monotherapy for 14 advanced metastatic triple‐negative breast cancer (mTNBC) patients refractory to systemic chemotherapy to develop a new type of cancer vaccine. The treatment protocol consisted of a weekly vaccination for 6 weeks, and there were no severe adverse events related to the vaccination throughout the trial. Increase of peptide‐specific IgG against the vaccinated human leukocyte antigen‐matched peptides, but not against the nonmatched peptides, was positively correlated with overall survival (OS) (P Immune boosting specific to the vaccinated human leukocyte antigen‐matched peptides at the cellular and humoral levels was observed in the vast majority of patients with refractory metastatic triple‐negative breast cancer, who completed all 6 vaccinations. |
| تدمد: | 1349-7006 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37e96b1175cd4acb5ea90957d57470fb https://pubmed.ncbi.nlm.nih.gov/32495455 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....37e96b1175cd4acb5ea90957d57470fb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497006 |
|---|